Risk of developing cancer increased by prediabetes
the ONA take:
According to a new meta-analysis published in the journal Diabetologia, the journal of the European Association for the Study of Diabetes, the risk of developing cancer is increased by prediabetes. That risk differs depending on the type of cancer. In the study, researchers evaluated 16 studies from Asia, the United States, Europe, and Africa.
The researchers found that prediabetes is linked with a 15% elevated risk of developing cancer overall. They found that the results were similar across age, cancer endpoint, duration of follow-up, and ethnicity. In addition, acknowledging that obesity is also linked to the development of cancer, researchers performed a sensitivity analysis that adjusted for body mass index and found that prediabetes was linked with a 22% increased risk of cancer.
When analyzing specific cancers, researchers found that prediabetes was associated with an increased risk of breast, colorectum, endometrium, liver, pancreas, and stomach cancer, but not linked with bladder, kidney, lung, ovary, or prostate cancer.
Prediabetes refers to a hemoglobin A1C (Hgb A1C) between 5.7% and 6.4%, with diabetes beginning when a patient has a Hgb A1C of 6.5% or higher.
That risk differs depending on the type of cancer.
A meta-analysis comprising 16 studies and 891,426 participants from various regions of the world shows that prediabetes increases the risk of cancer by 15%, with differing risks depending on the type of cancer. The study, published in Diabetologia (the journal of the European Association for the Study of Diabetes) is by Professor Yuli Huang, The First People's Hospital of Shunde, Daliang Town, Shunde District, China, and colleagues.
Prediabetes is a general term that refers to an intermediate stage between normoglycaemia and overt diabetes mellitus. It includes individuals with impaired glucose tolerance (IGT), impaired fasting glucose (IFG) or a combination of the two. Results to date from prospective cohort studies investigating the link between prediabetes and risk of cancer are controversial.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|